GE Healthcare this week released results from a pair of studies researching use of its MultiOmyx protein detection system in lymphoma and breast cancer.
The studies comprised an assessment of the company's nine-protein Hodgkin Lymphoma Profile assay, which it launched in July through its Clarient Diagnostic Services division, and an exploratory research effort using the system to evaluate known prognostic biomarkers in breast cancer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.